Market Spotlight: Cervical Cancer
Market Spotlight: Cervical Cancer
$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.
- Roche’s Avastin, Mylan’s biosimilar bevacizumab, Amgen’s Mvasi, and Pfizer’s Zirabev, which target vascular endothelial growth factor; Novartis’s Hycamtin, a topoisomerase I inhibitor; Pinnacle’s Photofrin, a photodynamic therapy; and Merck’s Keytruda, an anti-PD-1 antibody, are the marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II. Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, and intranasal formulations.
- High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase III trial results for Libtayo and axalimogene filolisbac, and topline Phase II trial results for tisotumab vedotin.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 41.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 11 licensing and asset acquisition deals involving cervical cancer drugs during 2015–20. The $727.5m license agreement signed in 2015 between Inovio and MedImmune for the exclusive rights to develop and market Inovio’s INO-3112 was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK and Spain lead the major European markets, while South Korea has the top spot in Asia.
- AstraZeneca has the highest number of ongoing clinical trials for cervical cancer, with 15 trials.
- AstraZeneca and Roche lead industry sponsors with the highest overall number of clinical trials for cervical cancer.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 LN-145 for Cervical Cancer (July 2, 2019)
23 Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
24 Mvasi for Cervical Cancer (June 25, 2019)
25 LN-145 for Cervical Cancer (May 31, 2019)
27 Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
28 LN-145 for Cervical Cancer (May 15, 2019)
30 Sacituzumab Govitecan for Cervical Cancer (April 29, 2019)
31 Nerlynx for Cervical Cancer (April 1, 2019)
32 Nerlynx for Cervical Cancer (March 18, 2019)
34 Axalimogene Filolisbac for Cervical Cancer (January 23, 2019)
35 Nerlynx for Cervical Cancer (January 11, 2019)
37 KEY UPCOMING EVENTS
38 KEY REGULATORY EVENTS
38 Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
38 Iovance Snags BTD For Cervical Cancer With Small Efficacy Sample Size
39 PROBABILITY OF SUCCESS
40 LICENSING AND ASSET ACQUISITION DEALS
40 US Merck Links With Tessa On Keytruda Combo For Cervical Cancer
41 PARENT PATENTS
42 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
47 BIBLIOGRAPHY
47 Prescription information
49 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2017–26
17 Figure 2: Overview of pipeline drugs for cervical cancer in the US
17 Figure 3: Pipeline drugs for cervical cancer, by company
18 Figure 4: Pipeline drugs for cervical cancer, by drug type
18 Figure 5: Pipeline drugs for cervical cancer, by classification
27 Figure 6: LN-145 for Cervical Cancer (May 31, 2019): Phase II – innovaTIL-04 (C-145-04)
30 Figure 7: LN-145 for Cervical Cancer (May 15, 2019): Phase II – innovaTIL-04 (C-145-04)
34 Figure 8: Nerlynx for Cervical Cancer (March 18, 2019): Phase II – SUMMIT – w/Fulvestrant (HER2-low/HER2mut)
37 Figure 9: Key upcoming events in cervical cancer
39 Figure 10: Probability of success in the cervical cancer pipeline
40 Figure 11: Licensing and asset acquisition deals in cervical cancer, 2015–20
41 Figure 12: Parent patents in cervical cancer
43 Figure 13: Clinical trials in cervical cancer
43 Figure 14: Top 10 drugs for clinical trials in cervical cancer
44 Figure 15: Top 10 companies for clinical trials in cervical cancer
44 Figure 16: Trial locations in cervical cancer
45 Figure 17: Cervical cancer trials status
46 Figure 18: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2017–26
15 Table 2: Marketed drugs for cervical cancer
19 Table 3: Pipeline drugs for cervical cancer in the US
23 Table 4: LN-145 for Cervical Cancer (July 2, 2019)
24 Table 5: Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
25 Table 6: Mvasi for Cervical Cancer (June 25, 2019)
26 Table 7: LN-145 for Cervical Cancer (May 31, 2019)
28 Table 8: Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
29 Table 9: LN-145 for Cervical Cancer (May 15, 2019)
31 Table 10: Sacituzumab Govitecan for Cervical Cancer (April 29, 2019)
32 Table 11: Nerlynx for Cervical Cancer (April 1, 2019)
33 Table 12: Nerlynx for Cervical Cancer (March 18, 2019)
35 Table 13: Axalimogene Filolisbac for Cervical Cancer (January 23, 2019)
36 Table 14: Nerlynx for Cervical Cancer (January 11, 2019)
42 Table 15: Historical global sales, by drug ($m), 2014–18
42 Table 16: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the